NEUE SERINPROTEASE-INHIBITOR-PROTEINE, DIESE ENTHALTENDE ARZNEIMITTEL, DNA-SEQUENZEN, DIE FUER DIESE PROTEINE CODIEREN UND VERFAHREN ZUR HERSTELLUNG DIESER PROTEINE, ARZNEIMITTEL UND DNA-SEQUENZEN

The invention relates to serine protease inhibitor proteins, medicaments containing them, DNA sequences coding for these proteins and methods for producing these proteins, medicaments and DNA sequences. These proteins correspond to the formula or sections thereof which comprise at least the sequence of positions 53-101, in which W is tyrosine or glutamic acid, X1, X2 and X3 are identical or different and each of these radicals is methionine or leucine, it also being possible for X3 to be phenylalanine, Y is proline or arginine, and Z is leucine or, if W is tyrosine and X1, X2 and X3 are leucine, is also isoleucine, and fusion proteins of these serine protease inhibitor proteins. The proteins are particularly distinguished by a strong inhibitory action against human leukocyte elastase and pronounced stability to oxidative breakdown. DNA sequences which code for the serine prolease inhibitor proteins and the expression of these proteins in suitable host organisms by means of various vectors, and the isolation of these proteins in pure biologically active form, and medicaments containing these products, are described. (Oligonucleotid = oligonucleotide> Figure 1a: DNA oligonucleotides D11, D12, D13, D11a, D12a and D13a (listed in the 3'->5' direction of synthesis) which are used in the synthesis of the DNA sequence "ALP gene 230" (Figure 2a). Figure 1b: DNA oligonucleotides D21, D22, D23, D21a, D22a and D23a (listed in the 3'->5' direction of synthesis) which are used in the synthesis of the DNA sequence "ALP gene 230" (Figure 2a). Figure 1c: DNA oligonucleotides D24, D25, D24a and D25a (listed in the 3'->5' direction of synthesis) which are used in the synthesis of the DNA sequence "ALP gene 240" (Figure 2b) commencing from the DNA sequence ALP gene 230.